Currently, immune checkpoint inhibitors (ICI) are becoming the standard first-line treatment for advanced NSCLC [85–87], and PD1, PDL1, and CTLA4 are mainly targets for ICI [88–92]. Here, CD274 is linked to non-small cell lung carcinoma.